The Analyst Landscape: 16 Takes On Taysha Gene Therapies
Portfolio Pulse from Benzinga Insights
Over the past three months, 16 analysts have shared their insights on Taysha Gene Therapies (NASDAQ:TSHA), with opinions ranging from bullish to bearish. The average 12-month price target has increased by 20.07% to $7.06. Analysts have maintained or raised their ratings, with notable actions including Jefferies raising its price target from $2.00 to $8.00.
June 17, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have shown a positive outlook on Taysha Gene Therapies, with the average 12-month price target increasing by 20.07% to $7.06. Notable actions include Jefferies raising its price target from $2.00 to $8.00.
The increase in the average 12-month price target and the positive actions from analysts, such as Jefferies raising its price target significantly, indicate a bullish sentiment. This is likely to positively impact TSHA's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100